H2020-NMP-CSA-2014Sub call of: H2020-NMP-2014-2015
|Planned Opening date||11-12-2013|
|Publication date||11-12-2013||Deadline Date||06-05-2014 17:00:00 (Brussels local time)|
|Total Call Budget||€12,500,000||Main Pillar||Industrial Leadership|
|Status||Closed||OJ reference||OJ C361 of 11 December 2013|
Specific challenge: Many innovative nano-biomedical developments are initiated by small companies. However, they often miss the necessary knowledge of the regulatory requirements for translation of their ideas, of the market and of the financial aspects of funding the developments and the business. The development and supply chain also show shortcomings. SMEs are often fragmented, dispersed and rarely organised in representative associations to address these problems with the result of missed opportunities for innovation. This is especially true in nanomedicine, covering diagnostics, therapeutics and regenerative medicine.
Scope: In order to alleviate this problem, the ETP Nanomedicine developed the concept of a 'Translation Hub'. This Coordination and Support Action shall provide advice and follow-up at all stages of the research and development and provide examples of best practice to European R&D teams in nano-bio-medicine. It shall provide SMEs and other organisations with a technological and business oriented assessment of their technologies and provide business advice before engaging further resources and efforts for preclinical and clinical tests.
The Coordination and Support Action shall network SMEs, aiming to improve their knowledge of translation in a sustainable way; to build bridges with academia and hospitals; and to link them with large companies and investors. It shall provide education and training in translation and entrepreneurship to academia and SMEs and help the showcasing of preclinical or early clinical proofs of concepts to large companies and investors. It will assist nanomedicine research projects in better anticipating the requirements of the translation process, in order to improve the probability of the developments to reach the market. It will also seek synergies with other relevant SME support networks.
The Commission considers that proposals requesting a contribution from the EU between EUR 1 and 2 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts. No more than one proposal will be funded.
· Reinforce support to European SMEs and academia as drivers of innovations in nanomedicine, by assisting them in the development of their bottom-up ideas, going from pre-clinical proof of concept to late clinical trials.
· Improve the innovation capacity of the European nano-bio-medical sector – especially at the level of SMEs - through catalysing a more effective translation process from research into industrial marketable products.
· Improve the knowledge in the research community of the translation, regulatory and business aspects of new nano-biomedical developments, leading to more efficient use of resources and research.
· Improve the capacities of SME networks regarding technologies and facilities that are required to facilitate the transfer of scientific knowledge to market or to facilitate clinical studies.
Type of action: Coordination and Support Action
Please read carefully all provisions below before the preparation of your application.
- List of countries and applicable rules for funding: described in part A of the General Annexes of the General Work Programme.
- Eligibility and admissibility conditions: described in part B and C of the General Annexes of the General Work Programme.
3.1 Evaluation criteria and procedure, scoring and threshold: described in part H of the General Annexes of the General Work Programme, with the following exceptions:
For single-stage and second-stage evaluations, the threshold for the criteria Excellence and Impact will be 4. The overall threshold, applying to the sum of the three individual scores, will be 12.
In case of equal overall scores in the ranked list, the priority order of proposals will be established in accordance with part H of the General Annexes, except that proposals will be ranked on the basis of individual scores for the Impact criterion before the Excellence criterion.
3.2 Guide to the submission and evaluation process
- Proposal page limits and layout: Please refer to Part B of the standard proposal template.
- Indicative timetable for evaluation and grant agreement:
Information on the outcome of one-stage evaluation: maximum 5 months from the final date for submission.
Signature of grant agreements: maximum 3 months from the date of informing successful applicants.
- Provisions, proposal templates and evaluation forms for the type(s) of action(s) under this topic:
Coordination and Support Action:
Specific provisions and funding rates
Standard proposal template (administrative forms and structure of technical annex)
Standard evaluation form
Annotated Model Grant Agreement
- Additional provisions:
Horizon 2020 budget flexibility
Technology readiness levels (TRL) – where a topic description refers to TRL, these definitions apply.
Financial support to Third Parties – where a topic description foresees financial support to Third Parties, these provisions apply.
- Open access must be granted to all scientific publications resulting from Horizon 2020 actions, and proposals must refer to measures envisaged. Where relevant, proposals should also provide information on how the participants will manage the research data generated and/or collected during the project, such as details on what types of data the project will generate, whether and how this data will be exploited or made accessible for verification and re-use, and how it will be curated and preserved.
You can download the same documents as one zip file from the call page
- Legal basis - Specific Programme H2020 en
- WP H2020 - 1. Introduction en
- WP H2020 - draft corrigendum en
- WP H2020 - 5. Introduction to Leadership in enabling and industrial technologies (LEITs) en
- WP H2020 - 5ii. Nanotechnologies, advanced materials, advanced manufacturing and processing, biotechnology en
- Legal basis - Framework Programme H2020 en
- Legal basis - Rules for Participation en
- WP H2020 - 19. General Annexes en
No submission system is open for this topic.